RxDoctor Payments Data

Reid Hopkins, MD

Gastroenterology · Norwalk, CTNPI 1598102626

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Johnson & Johnson at 41.8% of the total. 2025 is the largest year on record at $705, 5.6 times the $125 reported in 2021. That places this record below the midpoint for gastroenterology clinicians in CT, where the typical reported total is $3,356.

$957in general payments, 2019–2025

Across 24 payments — averaging $39.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$400
  • Takeda Pharmaceuticals U.S.A., Inc.$356
  • AbbVie$157
  • Boston Scientific$27
  • Olympus America Inc.$17

What the payments were for

  • Food & beverage$957100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$957 in reported general payments places this provider in the 30th percentile of 326 gastroenterology providers in Connecticut.

See all gastroenterology providers in Connecticut

Medicare billing

Part B allowed, 2024
$97,278
Medicare patients
405
Services billed
708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide26$24,394
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates87$5,470
ClenpiqSod Picosulf/Mag Ox/Citric Ac17$3,000
Omeprazole135$2,448
Mesalamine11$2,249
Famotidine55$2,163
Colestipol Hcl30$1,951
Pantoprazole Sodium139$1,837
Lubiprostone13$1,180
Esomeprazole Magnesium26$1,091
Lansoprazole19$718
Dicyclomine Hcl20$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$157$24,39426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 326 gastroenterology providers in Connecticut.

Other gastroenterology in Norwalk

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →